How to pay the least
From
$13 for 30 tablets
Generic tamoxifen from Rx Outreach, by mail. Pick the strength on your label for its own price.
What to do
- Make a free account on rxoutreach.org. Ask your prescriber to send the prescription there, or Rx Outreach can transfer it.Open Rx Outreach
- Order generic tamoxifen. It comes by mail.
Other ways
Need it today? From $15.30 for 30 tablets with the free Team Cuban Card, at pharmacies that take it. Get the free card and show it there.
See the price and get the cardEvery company’s tamoxifen is rated by the FDA to work the same, so any pharmacy can fill your prescription with the one it stocks.
Where to buy it
Pharmacies’ own cash prices for generic tamoxifen, lowest first.
Pick up in storeDelivered
- Delivered: Amazon RxPass $5a month10 mgCovers all your RxPass medicines togetherPrime members only · $139 a year · Free delivery · Not in California or Washington, or with Medicaid or CHIP
- Delivered: Cost Plus Drugs from $8.21for 30 tablets10 mg $8.21 · 20 mg $8.45Plus $5.25 shipping
- Delivered: Amazon Pharmacy from $11.60for 30 tablets10 mg $11.60 · 20 mg $19.36Prime members only · $139 a year · Free delivery · Prime price: limits on some medicines if you're over 65 or have Medicare, Medicaid or TRICARE
- Delivered: Rx Outreach from $13for 30 tablets10 mg: $13 for 30 tablets · 90 tablets: $2520 mg: $16 for 30 tablets · 90 tablets: $35Free delivery
- Pick up in store: Team Cuban Card from $15.30for 30 tablets10 mg $15.30 · 20 mg $16.48Free card · Kroger, Albertsons, Safeway, Meijer and many local pharmaciesFind a pharmacy that takes it
- Pick up in store: Costco $46.99for 90 tablets20 mgMembers only · $65 a yearFind the nearest store
- Pick up in store: Walgreens + Optum Perks $28.01for 30 tablets20 mgFree Optum Perks coupon · not with insuranceFind the nearest store
- Delivered: Optum Perks $36.04for 30 tablets20 mgPlus $5 shipping · Not with insurance
- Pick up in store: Sam's Club See its pricePlus members only · $120 a yearFind the nearest store
From each pharmacy’s own site, read November 17, 2026. Confirm the price before you fill.
About these prices
Prices change, can differ by store and state, and may depend on the strength and how many you take. With insurance, ask what your plan charges; it can be less.
Who makes it
4 companies sell tamoxifen in this form, each one rated by the FDA as a substitute for the others. A pharmacy fills whichever one it stocks. To get a certain maker, ask for it by name; most pharmacies can order it in a day or two.
-
Actavis Pharma10 mg, 20 mg
Has lactose
How it looks, what’s in it, NDCs
10 mg White, round, 8 mm, marked “2232 / WPI”
Package NDC Bottle of 60 0591-2472-60 Bottle of 180 0591-2472-18 20 mg White, round, 10 mm, marked “2233 / WPI”
Package NDC Bottle of 30 0591-2473-30 Bottle of 90 0591-2473-19 Inactive ingredients: croscarmellose sodium, lactose monohydrate, magnesium stearate, cellulose, microcrystalline, starch, corn
-
Aurobindo Pharma10 mg, 20 mg
Has lactose · Made by Eugia Pharma Specialities
Product page on aurobindousa.com
How it looks, what’s in it, NDCs
10 mg White to off-white, round, 7 mm, marked “T10”
Package NDC Bottle of 60 59651-299-60 20 mg White to off-white, round, 9 mm, marked “T20”
Package NDC Bottle of 30 59651-300-30 Bottle of 90 59651-300-90 Inactive ingredients: starch, corn, croscarmellose sodium, hypromellose 2910 (5 mpa.s), lactose monohydrate, magnesium stearate, polyethylene glycol 400, povidone k30, titanium dioxide
-
Dr. Reddy’s Laboratories10 mg, 20 mg
Has lactose
How it looks, what’s in it, NDCs
10 mg White, round, 7 mm, marked “MYX / 642”
Package NDC Bottle of 60 75907-058-60 Bottle of 1000 75907-058-10 20 mg White, round, 9 mm, marked “MYX / 643”
Package NDC Bottle of 30 75907-059-30 Bottle of 1000 75907-059-10 Inactive ingredients: croscarmellose sodium, lactose monohydrate, magnesium stearate, hypromellose 2910 (5 mpa.s), polyethylene glycol 400, povidone k30, starch, corn, titanium dioxide
-
Mylan Pharmaceuticals10 mg, 20 mg
Has lactose · Being phased out; sold until April 2027
How it looks, what’s in it, NDCs
10 mg White, round, 7 mm, marked “M / 144”
Package NDC Bottle of 60 0378-0144-91 20 mg White to off-white, round, 10 mm, marked “M / 274”
Package NDC Bottle of 30 0378-0274-93 Inactive ingredients: anhydrous lactose, silicon dioxide, crospovidone, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate
Who sells it: FDA and Medicaid records, updated weekly. Each maker’s page, card and program is from its own site.
What to say at the pharmacy
“Before you fill it, what would I pay for generic tamoxifen?”
Paying cash? Ask for the cash price. With insurance, ask what your plan charges.
What it’s used for
- Breast cancer
- Lowering the risk of invasive breast cancer after DCIS
- Lowering the risk of breast cancer in high-risk women
What the FDA label says
Metastatic Breast Cancer
Tamoxifen citrate tablets are effective in the treatment of metastatic breast cancer in women and men. In premenopausal women with metastatic breast cancer, tamoxifen citrate tablets are an alternative to oophorectomy or ovarian irradiation. Available evidence indicates that patients whose tumors are estrogen receptor positive are more likely to benefit from tamoxifen citrate tablet therapy.
Adjuvant Treatment of Breast Cancer
Tamoxifen citrate tablets are indicated for the treatment of node-positive breast cancer in postmenopausal women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. In some tamoxifen adjuvant studies, most of the benefit to date has been in the subgroup with four or more positive axillary nodes.
Tamoxifen citrate tablets are indicated for the treatment of axillary node-negative breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation.
The estrogen- and progesterone-receptor values may help to predict whether adjuvant tamoxifen citrate tablet therapy is likely to be beneficial.
Tamoxifen citrate tablets reduce the occurrence of contralateral breast cancer in patients receiving adjuvant tamoxifen citrate tablet therapy for breast cancer.
Ductal Carcinoma in Situ (DCIS)
In women with DCIS, following breast surgery and radiation, tamoxifen citrate tablets are indicated to reduce the risk of invasive breast cancer (see BOXED WARNING). The decision regarding therapy with tamoxifen citrate tablets for the reduction in breast cancer incidence should be based upon an individual assessment of the benefits and risks of tamoxifen citrate tablet therapy.
Current data from clinical trials support 5 years of adjuvant tamoxifen citrate tablet therapy for patients with breast cancer.
Reduction in Breast Cancer Incidence in High Risk Women
Tamoxifen citrate tablets are indicated to reduce the incidence of breast cancer in women at high risk for breast cancer. This effect was shown in a study of 5 years planned duration with a median follow-up of 4.2 years. Twenty-five percent of the participants received drug for 5 years. The longer-term effects are not known. In this study, there was no impact of tamoxifen citrate tablets on overall or breast cancer-related mortality (see BOXED WARNING).
Tamoxifen citrate tablets are indicated only for high risk women. "High risk" is defined as women at least 35 years of age with a 5 year predicted risk of breast cancer ≥ 1.67%, as calculated by the Gail Model.
Examples of combinations of factors predicting a 5 year risk ≥ 1.67% are:
Age 35 or older and any of the following combination of factors:
- One first-degree relative with a history of breast cancer, two or more benign biopsies, and a history of a breast biopsy showing atypical hyperplasia; or
- At least two first-degree relatives with a history of breast cancer, and a personal history of at least one breast biopsy; or
- LCIS
Age 40 or older and any of the following combination of factors:
- One first-degree relative with a history of breast cancer, two or more benign biopsies, age at first live birth 25 or older, and age at menarche 11 or younger; or
- At least two first-degree relatives with a history of breast cancer, and age at first live birth 19 or younger; or
- One first-degree relative with a history of breast cancer, and a personal history of a breast biopsy showing atypical hyperplasia.
Age 45 or older and any of the following combination of factors:
- At least two first-degree relatives with a history of breast cancer and age at first live birth 24 or younger; or
- One first-degree relative with a history of breast cancer with a personal history of a benign breast biopsy, age at menarche 11 or less and age at first live birth 20 or more.
Age 50 or older and any of the following combination of factors:
- At least two first-degree relatives with a history of breast cancer; or
- History of one breast biopsy showing atypical hyperplasia, and age at first live birth 30 or older and age at menarche 11 or less; or
- History of at least two breast biopsies with a history of atypical hyperplasia, and age at first live birth 30 or more.
Age 55 or older and any of the following combination of factors:
- One first-degree relative with a history of breast cancer with a personal history of a benign breast biopsy, and age at menarche 11 or less; or
- History of at least two breast biopsies with a history of atypical hyperplasia, and age at first live birth 20 or older.
Age 60 or older and:
- 5 year predicted risk of breast cancer ≥ 1.67%, as calculated by the Gail Model.
For women whose risk factors are not described in the above examples, the Gail Model is necessary to estimate absolute breast cancer risk. Healthcare Professionals can obtain a Gail Model Risk Assessment Tool by dialing Mylan Pharmaceuticals Inc. at 1-877-446-3679 (1-877-4-INFO-RX).
There are insufficient data available regarding the effect of tamoxifen citrate tablets on breast cancer incidence in women with inherited mutations (BRCA1, BRCA2) to be able to make specific recommendations on the effectiveness of tamoxifen in these patients.
After an assessment of the risk of developing breast cancer, the decision regarding therapy with tamoxifen citrate tablets for the reduction in breast cancer incidence should be based upon an individual assessment of the benefits and risks of tamoxifen citrate tablet therapy. In the NSABP P-1 trial, tamoxifen citrate tablet treatment lowered the risk of developing breast cancer during the follow-up period of the trial, but did not eliminate breast cancer risk (see CLINICAL PHARMACOLOGY: Table 3).
Source: the FDA label for Tamoxifen (Mylan Pharmaceuticals Inc.), July 2, 2021. Full label on DailyMed
Good to know
- Different companies’ tamoxifen can look different. The FDA requires each to work the same way.
- Don’t stop or change a medicine without talking to your pharmacist or prescriber.
Prices checked November 17, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/tamoxifen/